Javascript must be enabled to continue!
Duchenne Muscular Dystrophy: Clinical Characteristics, Molecular Mechanisms and Management
View through CrossRef
The dystrophinopathies encompass a range of X-linked muscle disorders varying from mild to severe, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy (DCM). DMD typically manifests in early childhood and progresses rapidly, with affected children becoming wheelchair-dependent by the age of 12. Increased serum CK levels are detected in almost all DMD patients. Pathogenic variants in the DMD gene affect dystrophin expression, leading to DMD. More than four thousand pathogenic variants have been identified in the DMD gene. deletions of one or more exons are the most common variants in the DMD gene and are found in 60%-70% of patients. With current genetic methods, it is possible to elucidate the molecular etiology in approximately 95% of patients. Penetrance of DMD is complete in males. The penetrance varies in heterozygous carrier females and may depend, partly, X-chromosome inactivation (XCI) patterns. Since DMD has X-linked inheritance pattern, carrier screening should always be considered for mothers of boys with DMD. There are two important points to remember in genetic counseling for DMD. One is that 33% of DMD cases are sporadic (de novo), and the other is that the probability of germline mosaicism for DMD is 15%-20%. Sarcoglycanopathies, Emery-Dreifuss muscular dystrophy, and Barth syndrome are diseases that are included in the differential diagnosis of DMD. Since multiple systems can be affected in DMD patients, management ideally should be provided within a multidisciplinary care setting. Although corticosteroids have been shown to increase muscle strength in DMD patients and are frequently used, they are not a curative treatment. In recent years, antisense oligonucleotides and nonsense suppression therapies have emerged as variant-specific treatments. Also, several new and promising therapies have entered clinical trials or are on the horizon. In this chapter, in addition to this summary about DMD, more comprehensive information is provided.
Title: Duchenne Muscular Dystrophy: Clinical Characteristics, Molecular Mechanisms and Management
Description:
The dystrophinopathies encompass a range of X-linked muscle disorders varying from mild to severe, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy (DCM).
DMD typically manifests in early childhood and progresses rapidly, with affected children becoming wheelchair-dependent by the age of 12.
Increased serum CK levels are detected in almost all DMD patients.
Pathogenic variants in the DMD gene affect dystrophin expression, leading to DMD.
More than four thousand pathogenic variants have been identified in the DMD gene.
deletions of one or more exons are the most common variants in the DMD gene and are found in 60%-70% of patients.
With current genetic methods, it is possible to elucidate the molecular etiology in approximately 95% of patients.
Penetrance of DMD is complete in males.
The penetrance varies in heterozygous carrier females and may depend, partly, X-chromosome inactivation (XCI) patterns.
Since DMD has X-linked inheritance pattern, carrier screening should always be considered for mothers of boys with DMD.
There are two important points to remember in genetic counseling for DMD.
One is that 33% of DMD cases are sporadic (de novo), and the other is that the probability of germline mosaicism for DMD is 15%-20%.
Sarcoglycanopathies, Emery-Dreifuss muscular dystrophy, and Barth syndrome are diseases that are included in the differential diagnosis of DMD.
Since multiple systems can be affected in DMD patients, management ideally should be provided within a multidisciplinary care setting.
Although corticosteroids have been shown to increase muscle strength in DMD patients and are frequently used, they are not a curative treatment.
In recent years, antisense oligonucleotides and nonsense suppression therapies have emerged as variant-specific treatments.
Also, several new and promising therapies have entered clinical trials or are on the horizon.
In this chapter, in addition to this summary about DMD, more comprehensive information is provided.
Related Results
Role of Growth Factors and Apoptosis Proteins in Cognitive Disorder Development in Patients with Duchenne Muscular Dystrophy
Role of Growth Factors and Apoptosis Proteins in Cognitive Disorder Development in Patients with Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease; it occurs due to a mutation in the dystrophin protein gene; as a result, the protein is not synthesized an...
Duchenne De Boulogne: A Pioneer in Neurology and Medical Photography
Duchenne De Boulogne: A Pioneer in Neurology and Medical Photography
ABSTRACT:Guillaume-Benjamin-Amand Duchenne was born 200 years ago in Boulogne-sur-Mer (Pas-de-Calais, France). He studied medicine in Paris and became a physician in 1831. He pract...
A Nonsense Variant in COL6A1 in Landseer Dogs with Muscular Dystrophy
A Nonsense Variant in COL6A1 in Landseer Dogs with Muscular Dystrophy
Abstract
A novel canine muscular dystrophy in Landseer dogs was observed. We had access to five affected dogs from two litters. The clinical signs started at a few w...
The MRL Mitochondrial Genome Decreases Murine Muscular Dystrophy Severity
The MRL Mitochondrial Genome Decreases Murine Muscular Dystrophy Severity
It is well known that muscular dystrophy disease severity is controlled by genetic modifiers. The expectation is that by identifying these modifiers, we can illuminate additional t...
An analysis of prenatal diagnosis of 1408 fetuses with Duchenne/Becker muscular dystrophy family history
An analysis of prenatal diagnosis of 1408 fetuses with Duchenne/Becker muscular dystrophy family history
Abstract
Objective: In order to support clinical genetic counseling, investigate the best diagnostic method, and effectively manage the birth of DMD/BMD children in the Chi...
Dystrophin (DMD) Missense Variant in Cats with Becker-Type Muscular Dystrophy
Dystrophin (DMD) Missense Variant in Cats with Becker-Type Muscular Dystrophy
Muscular dystrophy due to dystrophin deficiency in humans is phenotypically divided into a severe Duchenne and milder Becker type. Dystrophin deficiency has also been described in ...
Diagnosis of Duchenne Muscular Dystrophy using Raman Hyperspectroscopy
Diagnosis of Duchenne Muscular Dystrophy using Raman Hyperspectroscopy
AbstractDuchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy and affects boys in infancy or early childhood. DMD is known to trigger progressi...
SPINAL MUSCULAR ATROPHY CLINICAL FEATURES, CLASSIFICATION, NATURAL HISTORY, GENETICS, DIAGNOSIS, COMPLICATIONS AND TREATMENT OF THE DISEASE
SPINAL MUSCULAR ATROPHY CLINICAL FEATURES, CLASSIFICATION, NATURAL HISTORY, GENETICS, DIAGNOSIS, COMPLICATIONS AND TREATMENT OF THE DISEASE
Introduction: Spinal muscular atrophy (SMA) is a complex neuromuscular disorder, it is the most usual autosomal recessively inherited lethal neuromuscular disease in pediatrics, it...

